particularly those involving novel compounds or first-in-human (FIH) dosing, ensuring participant safety is paramount. A Safety Review Committee (SRC), also known as a Dose Escalation Committee or Internal Safety Monitoring Committee, is a structured body tasked with independently evaluating emerging trial safety data. Its role is to make timely, evidence-based recommendations about dose escalation, cohort progression, or trial halting. In this tutorial, we’ll explore how SRCs are formed, how they operate, and their critical contribution to Phase 1 trial governance.

What Is a Safety Review Committee (SRC)?

An SRC is an independent or semi-independent group responsible for:

• Reviewing blinded or unblinded safety and pharmacokinetic data
• Recommending whether to escalate to the next dose cohort
• Halting or modifying the trial based on observed risks

When Are SRCs Required?

• FIH trials for new molecular entities or biologics
• Oncology and immune-modulating agents with narrow therapeutic windows
• SAD/MAD trials with staggered dose escalation
• Any trial involving novel modalities (e.g., gene therapies, RNA drugs)

SRC vs. DSMB: What’s the Difference?

• SRC: Internal, focused on early-phase safety oversight and dose decisions
• DSMB (Data and Safety Monitoring Board): Independent, more common in late-phase trials for efficacy/safety balance

Composition of the SRC

A well-functioning SRC typically includes:

• Medical Monitor – Clinical safety lead, may be blinded or unblinded
• Pharmacokineticist – Reviews exposure data vs. dose
• Biostatistician – Advises on variability and trend analysis
• Principal Investigator (optional) – Site-level clinical input
• Project Clinician / Program Head – Sponsor’s oversight

Additional members may include toxicologists, regulatory leads, or external experts if required.

Key Responsibilities

1. Safety Data Review

• Adverse events (AEs), serious AEs (SAEs), laboratory shifts
• ECG and telemetry findings
• Vital signs and tolerability assessments

2. Pharmacokinetic and Pharmacodynamic Review

• Compare observed Cmax and AUC with preclinical projections
• Look for exposure-dependent safety signals

3. Dose Escalation Decisions

• Review sentinel subject outcomes
• Make formal recommendation: proceed, pause, amend, or stop

4. Documentation and Communication

• Record minutes of meetings and final decision summary
• Communicate recommendation to sponsor and regulatory authorities

SRC Meeting Structure and Timeline

1. Trigger for Meeting

• Completion of a cohort (e.g., Day 7 post-dose safety follow-up)
• SAE reporting or unexpected lab abnormalities

2. Meeting Frequency

• Every time a cohort is completed or as per protocol-defined milestones
• Emergency meetings convened ad hoc if risk signals emerge

3. Typical Agenda

• Presentation of blinded/unblinded data
• Discussion of AE patterns, lab trends, ECG changes
• Review of PK data and dose-exposure projections
• Vote and documentation of recommendations

Blinded vs. Unblinded Review

• Blinded SRC: Suitable if placebo arm exists; avoids bias
• Unblinded SRC: Used when exposure or safety needs direct treatment linkage

Blinding decisions should be aligned with trial design and documented in the charter.

Regulatory and Ethical Oversight

FDA

• Recommends SRCs for FIH or high-risk molecules (per Guidance for Industry: “Estimating the Maximum Safe Starting Dose”)
• Expects protocol-defined stopping rules and governance documentation

EMA

• Requires risk mitigation plans to include internal review boards or SRCs
• Strong emphasis on sentinel dosing and staggered escalation

CDSCO (India)

• Mandatory internal review team for FIH and high-risk studies
• Any change in dose or schedule must be communicated with justification

Common Challenges and Mitigation Strategies

1. Scheduling Delays

• Solution: Set fixed meeting slots and prepare review packages early

2. Data Inconsistencies

• Solution: Ensure real-time data cleaning and monitoring by clinical ops

3. Lack of Consensus

• Solution: Use pre-agreed escalation criteria and voting processes

Best Practices for SRC Operations

• Draft an SRC Charter outlining composition, decision rules, timelines
• Designate a Chairperson and Secretary to coordinate and document
• Share consistent, clean datasets for objective review
• Maintain full transparency with ethics committees and regulators
• Store all minutes, decisions, and rationales as part of TMF (Trial Master File)